cytarabine has been researched along with abt-199 in 86 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (16.28) | 24.3611 |
| 2020's | 72 (83.72) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, NM; Bradner, JE; Feng, H; Harrold, I; Lan Zhang, G; Look, AT; Mansour, MR; McKeown, M; Nagykary, N; Sanda, T | 1 |
| Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J | 1 |
| Tiong, IS; Wei, AH | 1 |
| Hanmantgad, M; Liu, B; Liu, D; Narurkar, R; Song, Y; Zafar, W | 1 |
| Pollyea, DA; Sharma, P | 1 |
| Konopleva, M; Letai, A | 1 |
| Lancet, JE | 1 |
| Jordan, CT; Pollyea, DA | 1 |
| Flores-Jiménez, JA; González-Ramella, O; Pimentel-Morales, MA; Vega-Cortés, D; Zambrano-Velarde, MÁ | 1 |
| Agarwal, S; Chyla, B; Enjeti, A; Fakouhi, KM; Fiedler, W; Hayslip, J; Hong, WJ; Hou, JZ; Humerickhouse, R; Lee, S; Lin, TL; Popovic, R; Roboz, GJ; Salem, AH; Savona, M; Strickland, SA; Tiong, IS; Walter, RB; Wei, AH; Xu, T | 1 |
| DiNardo, C; Guerra, VA; Konopleva, M | 1 |
| Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH | 1 |
| Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M | 1 |
| Aldoss, I; Marcucci, G | 1 |
| DiNardo, CD; Wei, AH | 1 |
| DiNardo, CD; Richard-Carpentier, G | 1 |
| Jin, J; Li, J; Yu, W; Zhang, X | 1 |
| Emadi, A; Estey, E; Gale, RP; Karp, JE; Othus, M | 1 |
| Ferrara, F | 1 |
| Borthakur, G; Bueso-Ramos, C; Class, CA; Cortes, JE; Daver, N; DiNardo, CD; Do, KA; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Khoury, JD; Konopleva, M; Montalban-Bravo, G; Naqvi, K; Patel, K; Pierce, S; Ravandi, F; Routbort, M; Sasaki, K; Short, NJ; Takahashi, K | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Aplenc, R | 1 |
| Anagnostopoulos, A; Bergeron, J; Chyla, B; DiNardo, CD; Fiedler, W; Gopalakrishnan, S; Hayslip, J; Hou, JZ; Hu, Y; Ivanov, V; Jiang, Q; Kim, I; Laribi, K; McDonald, A; Mendes, W; Montesinos, P; Murthy, V; Novak, J; Pagoni, M; Panayiotidis, P; Samoilova, O; Stevens, DA; Wei, AH; Yamauchi, T | 1 |
| Aasebø, E; Bartaula-Brevik, S; Bruserud, Ø; Grønningsæter, IS; Hatfield, KJ; Reikvam, H; Tvedt, TH | 1 |
| Apel, A; Cohen, Y; Danylesko, I; Ganzel, C; Gino-Moor, S; Gural, A; Koren-Michowitz, M; Moshe, Y; Nachmias, B; Ofran, Y; Pasvolsky, O; Peretz, G; Ram, R; Rowe, JM; Vainstein, V; Wolach, O; Yeganeh, S; Yerushalmi, R; Zektser, M | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Beutel, G; Eder, M; Gabdoulline, R; Gohring, G; Heuser, M; Koenecke, C; Krauter, J; Markel, D; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Trummer, A | 1 |
| Estey, EH | 1 |
| Hosono, N; Negoro, E; Nishi, R; Okura, M; Shigemi, H; Yamauchi, T | 1 |
| Daver, N; DiNardo, CD; Fathi, AT; Pollyea, DA; Vyas, P; Wei, AH | 1 |
| Bewersdorf, JP; Giri, S; Stahl, M; Tallman, MS; Wang, R; Williams, RT; Zeidan, AM | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Alsdorf, W; Blohm, ME; Bokemeyer, C; Fiedler, W; Hecher, K; Karagiannis, P; Oelrich, J; Singer, D; Tallarek, AC; Waizenegger, JS; Wolschke, C | 1 |
| Gangat, N; Tefferi, A | 1 |
| Diao, S; DiNardo, C; DiPippo, AJ; Konopleva, M; Maiti, A; Nichols, ED; Ning, J; Qiao, W | 1 |
| Chen, EC; Garcia, JS | 1 |
| Chen, TC; Liao, PW; Teng, CJ; Wang, RC | 1 |
| Lin, N; Wang, L | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Al-Malki, M; Aldoss, I; Ali, H; Aribi, A; Arslan, S; Artz, A; Budde, E; Dadwal, S; Forman, S; Khaled, S; Koller, P; Marcucci, G; Nakamura, R; Ngo, D; Pullarkat, V; Salhotra, A; Sandhu, K; Snyder, DS; Stein, A; Zhang, J | 1 |
| Bell, T; Brown, A; Cappelleri, JC; Chan, G; Daniele, P; Tremblay, G | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Konopleva, M; Saxena, K | 1 |
| Apel, A; Basood, M; Canaani, J; Duek, A; Frisch, A; Ganzel, C; Gural, A; Hellman, I; Koren-Michowitz, M; Leibovitch, C; Moshe, Y; Ofran, Y; Stemer, G; Wolach, O; Zektser, M | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M | 1 |
| Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME | 1 |
| Davainis, L; Griskevicius, L; Maneikis, K; Peceliunas, V; Pileckyte, R; Staras, V; Trociukas, I; Vaitekenaite, V; Zucenka, A; Zvirblis, T | 1 |
| Asou, N; Dobashi, N; Honda, H; Ichikawa, S; Iida, H; Ishizawa, K; Jiang, Q; Komatsu, N; Kuroda, J; Kurokawa, M; Matsumura, I; Mendes, W; Miyamoto, T; Miyazaki, Y; Okubo, S; Takada, S; Usuki, K; Wei, A; Yamauchi, T; Yoshida, C | 1 |
| Alvarado, Y; Bivins, CA; Borthakur, G; Daver, NG; DiNardo, CD; Guerrero, JA; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Konopleva, MY; Maduike, RE; Maiti, A; Montalbano, KS; Ning, J; Pemmaraju, N; Pierce, S; Qiao, W; Rausch, CR; Ravandi, F; Short, NJ; Vaughan, K; Wade, A; Yilmaz, M | 1 |
| Daraskevicius, J; Everatt, V; Maneikis, K; Ringeleviciute, U; Vaitekenaite, V; Zucenka, A | 1 |
| Gai, Y; Lin, H; Liu, F; Liu, S; Lv, J; Su, Y; Wang, G; Wang, Y; Zhao, Q | 1 |
| Shimony, S; Stahl, M; Stone, RM | 1 |
| Kuang, P; Liu, T; Qin, Y | 1 |
| Fleischmann, M; Frietsch, JJ; Hammersen, J; Hilgendorf, I; Hochhaus, A; Prims, F; Schnetzke, U; Scholl, S; Schrenk, K; Thiede, C | 1 |
| Argüello, RJ; Aroua, N; Avet-Loiseau, H; Boet, E; Bosc, C; Bousard, A; Cabon, F; Cognet, G; Farge, T; Fournié, JJ; Fovez, Q; Gadaud, N; Gotanègre, M; Jarrou, L; Joffre, C; Kaoma, T; Kaphan, E; Kluza, J; Larrue, C; Marine, JC; Mazzotti, C; Mouchel, PL; Nicot, N; Picard, M; Poillet-Perez, L; Polley, N; Rambow, F; Récher, C; Sabatier, M; Sahal, A; Saland, E; Sarry, JE; Stuani, L; Su, X; Tamburini, J; Tiong, IS; Tosolini, M; Vergez, F; Wang, Y; Wei, AH | 1 |
| Babushok, DV; Carulli, A; Frey, NV; Freyer, CW; Gill, SI; Graveno, ME; Hexner, EO; Loren, AW; Luger, SM; Mangan, BL; Martin, ME; McCurdy, SR; Nietupski, R; Perl, AE; Porter, DL; Pratz, KW | 1 |
| Gong, P; Jing, Y; Wang, Y; Waxman, S; Yin, C; Zhang, J; Zhang, Z; Zhao, L | 1 |
| Benjamin, K; Bui, CN; Devine, J; DiNardo, CD; Fiedler, W; Fracchiolla, N; Ivanov, V; Jonas, BA; Kamalakar, R; Kim, I; Mendes, W; Montesinos, P; Novak, J; Ofran, Y; Panayiotidis, P; Pejsa, V; Potluri, J; Pratz, KW; Recher, C; Schuh, AC; Stevens, D; Turgut, M; Wei, AH; Wei, X; Yamamoto, K; Yeh, SP | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Frey, NV; Gill, SI; Hexner, EO; Hwang, WT; Loren, AW; Luger, SM; Maillard, IP; Margolis, D; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Stadtmauer, EA | 1 |
| Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Bravo, GM; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, SA; Xiao, L; Yilmaz, M | 1 |
| Andreeff, M; Bhalla, KN; Borthakur, G; Daver, NG; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Malla, R; Montalban-Bravo, G; Ohanian, M; Pemmaraju, N; Popat, UR; Quagliato, K; Rausch, CR; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Takahashi, K; Wang, X | 1 |
| Amit, O; Apel, A; Bar-On, Y; Frisch, A; Moshe, Y; Nachmias, B; Ofran, Y; Raanani, P; Ram, R; Shargian, L; Shimony, S; Vainstein, V; Wolach, O; Yeshurun, M | 1 |
| Ai, J; Arnall, J; Avalos, BR; Boselli, D; Chen, T; Chiad, Z; Chojecki, AL; Copelan, EA; Cruz, A; DiSogra, KY; Grunwald, MR; Karabinos, A; Knight, TG; Patel, R; Ragon, BK; Sanikommu, SR; Shah, NA; Symanowski, J; Verbyla, A | 1 |
| Ball, BJ; Koller, PB; Pullarkat, V | 1 |
| Abernathy, KM; Byrne, M; Chen, H; Gatwood, KS; Perciavalle, MA; Zakhari, MM | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Agrawal, N; Ahmed, R; Bansal, N; Bhurani, D; Halder, R; Mehta, P; Rainchwar, S; Singh, R; Verma, M | 1 |
| Annageldiyev, C; Cabot, MC; Claxton, DF; Conaway, MR; Costa-Pinheiro, P; Deering, TG; Feith, DJ; Fox, TE; Golla, U; Kester, M; Khokhlatchev, AV; Loughran, TP; Sharma, A; Shaw, JJP; Tan, SF; Ung, J | 1 |
| Bao, X; Carter, J; Dombkowski, A; Edwards, H; Ge, Y; Hege Hurrish, K; Hüttemann, M; Kalpage, HA; Kim, S; Li, J; Li, X; Ma, J; Qiao, X; Su, Y; Taub, JW; Wang, G | 1 |
| Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T | 1 |
| Billingham, L; Craddock, C; Dillon, R; Fox, S; Freeman, S; Hemmaway, C; Homer, E; Jackson, A; Knapper, S; Leahy, J; Mamwell, A; Maycock, S; Ommen, HB; Potter, N; Russell, N; Thomas, C; Wei, A | 1 |
| Aloyz, R; Fooks, K; Galicia-Vazquez, G; Gife, V; Hulea, L; Johnson, NA; Luo, V; Mercier, FE; Nouhi, Z; Orthwein, A; Poon, WWL; Rys, RN; Schcolnik-Cabrera, A | 1 |
| Belhabri, A; Bertoli, S; Billotey, NC; Bulabois, C; Cartet, E; Dumas, PY; Fornecker, L; Giltat, A; Guepin, GR; Guerineau, E; Houyou, D; Hunault, M; Kaphan, E; Lachenal, F; Laloi, L; Laribi, K; Michallet, AS; Michallet, M; Michel, C; Morisset, S; Paul, F; Pigneux, A; Puisset, F; Récher, C; Rocher, C; Santagostino, A; Simand, C; Simonet, MB; Tabrizi, R; Villate, A | 1 |
| Huang, X; Jin, J; Lou, Y; Ma, L; Mao, L; Ren, Y; Tong, H; Wang, H; Wang, Y; Wu, J; Xu, H; Yang, M; Yao, Y; Ye, X; Zhang, Y; Zhou, Y; Zhu, HH | 1 |
| Chang, LS; Chiou, JT; Hong, YC; Hsu, CC; Lee, YC | 1 |
| Ando, J; Asada, N; Dobashi, N; Honda, H; Iida, H; Ishizawa, K; Miyamoto, T; Mukai, H; Nishimura, Y; Okubo, S; Shinagawa, A; Soshin, T; Takada, S; Tsutsui, A; Usuki, K; Yamamoto, K; Yoshida, C | 1 |
| Ji, C; Jia, L; Li, G; Liu, J; Ma, D; Song, Y; Yang, H; Yang, X; Ye, F; Ye, J; Zheng, D; Zhou, Q; Zhou, Y | 1 |
| Jiang, S; Tang, Y; Zhao, L; Zhao, Y | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Carulli, A; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Lai, C; Loren, AW; Luger, SM; Maillard, IP; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Skuli, S; Stadtmauer, EA | 1 |
| Abbas, HA; Andreeff, M; Basyal, M; Borthakur, G; Dara, SI; Daver, N; DiNardo, CD; Garcia-Manero, G; Ishizawa, J; Issa, GC; Jabbour, EJ; Kantarjian, HM; Khoury, J; Kornblau, SM; Li, L; Loghavi, S; Muftuoglu, M; Naqvi, K; Pemmaraju, N; Pourebrahim, R; Ravandi, F; Senapati, J; Short, NJ; Yilmaz, M | 1 |
| Álvarez, N; Ayala, R; Carreño-Tarragona, G; García-Vicente, R; Garrido-García, V; Giménez, A; Linares, M; Martínez-López, J; Morales, ML; Ortiz-Ruiz, A; Reyes-Palomares, A; Rodríguez-García, A; Sánchez, R; Vincelle-Nieto, Á | 1 |
| Boudreau, LH; Gharib, E; Pichaud, N; Robichaud, GA; Veilleux, V | 1 |
| Agarwal, N; Ahmed, R; Bansal, N; Bhurani, D; Halder, R; Mirgh, SP; Shaikh, MR; Singh, B; Singh, R | 1 |
| Fredman, D; Gafter-Gvili, A; Raanani, P; Sherban, A; Shimony, S; Stahl, M; Wolach, O; Yeshurun, M | 1 |
| Betts, KA; Bui, CN; Dua, A; Lachaine, J; Li, X; Pratz, K; Schuh, AC; Song, J; Suh, HS | 1 |
| Chen, S; Han, Y; Qiu, H; Sun, A; Tang, X; Wang, Y; Wu, D; Xu, Y; Xue, S; Zhang, K; Zhang, X; Zhang, Y | 1 |
25 review(s) available for cytarabine and abt-199
| Article | Year |
|---|---|
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines | 2017 |
Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myelodysplastic Syndromes; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
BCL-2 inhibition in AML: an unexpected bonus?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Is the overall survival for older adults with AML finally improving?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Survival Rate | 2018 |
Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Sulfonamides | 2019 |
Venetoclax-based therapies for acute myeloid leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines | 2019 |
Single-agent and combination biologics in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Neoplasm Proteins; Sulfonamides; Survival Rate | 2019 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Drug Approval; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Staurosporine; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Acute myeloid leukemia: 2021 update on risk-stratification and management.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Sulfonamides; United States | 2020 |
New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Quinuclidines; Sulfonamides | 2020 |
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
New Treatment Options for Older Patients with Acute Myeloid Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Patient Selection; Stem Cell Transplantation; Sulfonamides | 2021 |
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2022 |
Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute | 2023 |
Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Nucleosides; Sulfonamides | 2022 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.
Topics: Aclarubicin; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, T-Lymphoid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2023 |
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute | 2023 |
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Cytarabine; Humans; Leukemia, Myeloid, Acute; Network Meta-Analysis; Treatment Outcome | 2023 |
10 trial(s) available for cytarabine and abt-199
| Article | Year |
|---|---|
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Sulfonamides | 2019 |
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine | 2020 |
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Sulfonamides; Survival Rate | 2020 |
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Sulfonamides; Treatment Outcome | 2020 |
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult | 2021 |
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Japan; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nuclear Proteins; Quality of Life; Standard of Care | 2022 |
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Tumor Lysis Syndrome | 2023 |
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Proteomics; Tumor Suppressor Protein p53; Young Adult | 2023 |
51 other study(ies) available for cytarabine and abt-199
| Article | Year |
|---|---|
BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Differentiation; Cell Line, Tumor; Cytarabine; Drug Synergism; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2014 |
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
Topics: Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Protein Stability; Sulfonamides | 2016 |
Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Sulfonamides | 2018 |
Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Salvage Therapy; Sulfonamides; Young Adult | 2019 |
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
Topics: Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Sulfonamides | 2019 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
Topics: Aclarubicin; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Male; Mutation; Neoplasm Proteins; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Sulfonamides | 2020 |
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Venetoclax for paediatric acute myeloid leukaemia: a step forward.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Child; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Sulfonamides | 2020 |
Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Cytarabine; Deoxyglucose; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Genetic Heterogeneity; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Mesenchymal Stem Cells; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Proteomics; Sulfonamides; Survival Analysis; Young Adult | 2020 |
Venetoclax is safe and efficacious in relapsed/refractory AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Retrospective Studies; Sulfonamides | 2020 |
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Factors; Sulfonamides; Tumor Lysis Syndrome | 2021 |
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Clofarabine; Cytarabine; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines; Sulfonamides | 2020 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Pregnancy; Pregnancy Complications, Neoplastic; Sulfonamides | 2021 |
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Fluid Therapy; Humans; Hydroxyurea; Incidence; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukocytosis; Male; Middle Aged; Phosphate-Binding Proteins; Phosphorus; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Sulfonamides; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2021 |
Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Selection; Sulfonamides | 2020 |
Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Panniculitis; Sulfonamides; Withholding Treatment | 2021 |
Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Remission Induction; Sulfonamides; Treatment Outcome | 2021 |
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Sulfonamides | 2021 |
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2021 |
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Salvage Therapy; Sulfonamides; Vidarabine | 2021 |
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Propensity Score; Sulfonamides | 2021 |
Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Dactinomycin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Salvage Therapy; Sulfonamides; Survival Rate | 2021 |
Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2022 |
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Topics: Adult; Aged; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Sulfonamides | 2022 |
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides | 2022 |
Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Topics: Aged; Animals; Apoptosis; Apoptosis Regulatory Proteins; Artesunate; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2022 |
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Fatigue; Humans; Leukemia, Myeloid, Acute; Quality of Life; Sulfonamides | 2022 |
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Quality of Life; Retrospective Studies; Sulfonamides | 2022 |
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Sulfonamides; Vidarabine; Young Adult | 2022 |
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Sulfonamides | 2022 |
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Hospitalization; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Real-world analysis of tumor lysis syndrome in patients started on venetoclax combination for acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Tumor Lysis Syndrome | 2023 |
Pneumocystis jirovecii pneumonia [PJP]: An unrecognized concern in AML patients on Venetoclax.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Pneumocystis carinii; Pneumonia, Pneumocystis; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Ceramides; Cytarabine; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
Topics: Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Leukemia, Myeloid, Acute; Mice; Mitochondria; Phosphatidylinositol 3-Kinases | 2022 |
Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Monitoring; Humans; Itraconazole; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Eukaryotic Initiation Factor-4A; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2 | 2022 |
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2023 |
Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger; U937 Cells | 2023 |
Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Leukemia, Myeloid, Acute; Mice; Sulfonamides | 2023 |
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies | 2023 |
Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; RNA Splicing; Sulfonamides | 2023 |
Platelet-derived microparticles provoke chronic lymphocytic leukemia malignancy through metabolic reprogramming.
Topics: Antineoplastic Agents; Cell-Derived Microparticles; Cytarabine; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell | 2023 |
FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines".
Topics: Adult; Anthracyclines; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies; Vidarabine | 2023 |
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Core Binding Factors; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2023 |